Changes in body composition during androgen deprivation therapy for prostate cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 2, 2002, Pages 599-603

  Smith, Matthew R ^a   Finkelstein, Joel S ^b   McGovern, Francis J ^b   Zietman, Anthony L ^a   Fallon, Mary Anne ^b   Schoenfeld, David A ^a   Kantoff, Philip W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GONADORELIN AGONIST; LEUPRORELIN; PAMIDRONIC ACID;

ADVANCED CANCER; AGED; ARTICLE; BODY COMPOSITION; BODY DISTRIBUTION; BODY FAT; BODY WEIGHT; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAT BODY; HORMONAL THERAPY; HUMAN; LEAN BODY WEIGHT; MALE; MUSCLE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

EID: 0036173823     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.2.8299     Document Type: Article

References (41)

1. Cancer statistics, 2001
2. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
3. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
4. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
5. Prostate specific antigen only progression of prostate cancer
6. Testosterone, body composition and aging
7. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age
8. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels
9. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men
10. Testosterone therapy in glucocorticoid-treated men
11. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism
12. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men
13. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer
14. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer
15. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
16. Lean body mass estimation by bioelectrical impedance analysis: A four-site cross-validation study
17. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism
18. Fatigue in patients with prostate cancer receiving hormone therapy
19. Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity
20. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists
21. Health implications of obesitv: An NIH Consensus Development Conference
22. Androgens and abdominal obesity
23. Abdominal obesity
24. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men
25. Treatment of prostate cancer with gonadotropm-releasing hormone analogue: Effect on lipoprotein[a]
26. Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels
27. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a)
28. Androgens and erythropoiesis
29. Leuprolide versus diethylstibestrol for metastatic prostate cancer
30. Leuprolide with and without fiutamide in advanced prostate cancer
31. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade
32. Osteoporosis after orchiectomy for prostate cancer
33. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
34. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer
35. Progressive osteoporosis during androgen deprivation therapy for prostate cancer
36. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy
37. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma
38. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens
39. Frailty in older adults: Evidence for a phenotype
40. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy
41. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study